



FFul 1A

PATENT
Customer No. 22,852
Attorney Docket No. 7579.0015-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Graham Edmund KELLY et al.) Confirmation No. 6037
Serial No.: 10/600,004) Group Art Unit: 1614
Filed: June 18, 2003) Examiner: Cybille DELACROIX-MUIRHEID
For: CARDIOVASCULAR AND)
BONE TREATMENT USING)
ISOFLAVONES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed foreign and non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. Should the Examiner conclude that any of these claims form the basis of a rejection, the Examiner is invited to contact the undersigned.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any additional fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 28, 2005

By: Deborah J. Acker
Deborah J. Acker
Reg. No. 48,916

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>				<i>Application Number</i>	10/600,004
				<i>Filing Date</i>	June 18, 2003
				<i>First Named Inventor</i>	KELLY et al.
				<i>Art Unit</i>	1614
				<i>Examiner Name</i>	Cybille DELACROIX-MURHEID
				<i>Attorney Docket Number</i>	07579-0015-01000
Sheet	1	of	1		

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		JP 61-246124	Nov. 1, 1986	Yamanouchi Pharmaceutical Co.		Yes
		JP 1-258669	Oct. 16, 1989	Kikkoman Corp.		Yes
		WO 97/46208 A2, A3	Dec. 11, 1997	Mt. Sinai School of Medicine of the City of New York		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.